Data type | Source | Information provided | Time frame |
Household survey data | Provided by authors of Reference 25. | % of patients consuming medicine, by API and dose | 2018 |
Detailed distribution or dispensing data | Secondary data provided by facilities | Volumes distributed or dispensed by API, dose, brand and month: district warehouse; two primary health centres; one private distributor; two pharmacies | April–October 2020 |
National aggregate sales volume | IQVIA public health | Sales volume by API and dose, by INN status and outlet sector (hospital or retail). | April–October 2020 |
Listing of pharmacies | District health office, verified by research team | Location of pharmacies and medicine shops in eight study villages and four neighbouring market centres*; private healthcare providers in eight study villages | 2019 data received March 2020, verified October 2020 |
Listing of healthcare providers and medicine shops | Internet search and public directories, verified by research team | Location of private healthcare providers and medicine shops in eight study villages | October–November 2020 |
Rapid survey of pharmacies and medicine shops | Primary data | Estimate of patients served per day with any study medicine | October–November 2020 |
Rapid survey of healthcare providers | Primary data | Estimate of patients served per day with any study medicine, medicines sold, source of medicines | November–December 2020 |
*These bordering locations are frequent shopping destinations for residents of the eight villages.
API, active pharmaceutical ingredient; INN, international non-proprietary name.